Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Non-Interventional Study to Assess the Prevalence of PD-L1 Expression in the First-Line Setting of Locally Advanced/Unresectable or Metastatic Urothelial Carcinoma

NCT03788746 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT03788746
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03788746 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Non-Interventional Study to Assess the Prevalence of PD-L1 Expression in the First-Line Setting of Locally Advanced/Unresectable or Metastatic Urothelial Carcinoma
Lead sponsor
AstraZeneca
Phase
Observational
Overall status
Completed
Start date
January 17, 2019
Completion date
May 25, 2023
Enrollment
181 (actual)
Sites
58

Conditions

As the registry lists them; a condition with its own page is linked.

urothelial carcinoma